We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 418.32%
This Fund
S&P 500
This Quarter Est. Return
+40.72%
1 Year Est. Return
+418.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$158M
AUM Growth
+$18.4M
Cap. Flow
-$14.8M
Cap. Flow %
-9.34%
Top 10 Hldgs %
63.75%
Holding
43
New
8
Increased
13
Reduced
9
Closed
11

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$9.26M
2
RVMD icon
Revolution Medicines
RVMD
+$7.46M
3
GMAB icon
Genmab
GMAB
+$6.22M
4
COGT icon
Cogent Biosciences
COGT
+$4.13M
5
TRVI icon
Trevi Therapeutics
TRVI
+$3.97M

Top Sells

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$16.9M
2
URGN icon
UroGen Pharma
URGN
+$5.31M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.92M
4
IMVT icon
Immunovant
IMVT
+$4.55M
5
IQV icon
IQVIA
IQV
+$4.38M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

1 2

Similar funds

FCM
Flagship Capital Management Media, Pennsylvania $158M AUM
SF
Seek First Campbell, California $158M AUM 38.46% 1-Year Est. Return
CCA
Collaborative Capital Advisors New York $158M AUM
VFIA
Virtus Fixed Income Advisers Hartford, Connecticut $158M AUM 0.51% 1-Year Est. Return
BTC
Bank & Trust Company Litchfield, Illinois $158M AUM 35.48% 1-Year Est. Return
SWM
Schwallier Wealth Management Grand Rapids, Michigan $158M AUM 16.81% 1-Year Est. Return
AWA
AGH Wealth Advisors Wichita, Kansas $158M AUM 34.31% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return

Superstring Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Superstring Capital Management held 43 positions worth $158M, up 13% from $140M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Superstring Capital Management withdrew a net $14.8M in Q2 2026, closing 11 positions and reducing 9 holdings. Its most notable exit was Summit Therapeutics, an estimated $16.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Revolution Medicines worth $9.56M.

  • Superstring Capital Management's largest Q2 2026 buy was Revolution Medicines: 51,053 shares worth $9.56M.
  • Superstring Capital Management added most to Axsome Therapeutics in Q2 2026, an estimated $9.26M increase.
  • Superstring Capital Management's biggest Q2 2026 reduction was UroGen Pharma, cutting an estimated $5.31M.
  • Superstring Capital Management fully exited Summit Therapeutics in Q2 2026, selling an estimated $16.9M.
  • Superstring Capital Management's ten largest holdings make up 64% of its $158M portfolio in Q2 2026.
  • Superstring Capital Management opened 8 new positions and closed 11 in Q2 2026.
  • Superstring Capital Management's portfolio value rose 13% quarter-over-quarter to $158M.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.